Manufacturer of Controlled Substances; Notice of Registration, 12635 [E7-4825]

Download as PDF sroberts on PROD1PC70 with NOTICES Federal Register / Vol. 72, No. 51 / Friday, March 16, 2007 / Notices brings national attention to the problem to increase public awareness of the need for prevention and enhanced victim services. This meeting will primarily focus on the Committee’s work and the federal government’s response to violence against women; there will, however, be an opportunity for public comment on the Committee’s role in providing general policy guidance on implementation of the Violence Against Women Act of 1994, the Violence Against Women Act of 2000, the Violence Against Women Act of 2005 and related laws. April 3, 2007, from 8:30 a.m. until 5 p.m. and on April 4, 2007 from 8:30 a.m. until 12 noon, and will include breaks and a working lunch. Time will be reserved for public comment on April 3 beginning at 9 a.m. and ending at 9:30 a.m. See the section below for information on reserving time for public comment. Access: This meeting will be open to the public but registration on a spaceavailable basis is required. Persons who wish to attend must register at least six (6) days in advance of the meeting by contacting Sandy Lonick by e-mail at: Saundra.Lonick@usdoj.gov; or fax: (202) 307–3911. All attendees will be required to sign in at the meeting registration desk. Please bring photo identification and allow extra time prior to the meeting. The meeting site is accessible to individuals with disabilities. Individuals who require special accommodations in order to attend the meeting should notify Sandy Lonick by e-mail at: Saundra.Lonick@usdoj.gov; or fax at: (202) 307–3911, no later than March 23, 2007. After this date, we will attempt to satisfy accommodation requests, but cannot guarantee the availability of any requests. Written Comments: Interested parties are invited to submit written comments by March 23, 2007 to Sandy Lonick at The National Advisory Committee on Violence Against Women, 800 K Street, NW., Ste. 920, Washington, DC 20530. Comments may also be submitted by email at Saundra.Lonick@usdoj.gov; or fax at (202) 307–3911. Public Comment: Persons interested in participating during the public comment period of the meeting, which will discuss the implementation of the Violence Against Women Act of 1994 and the Violence Against Women Act of 2000, the Violence Against Women Act of 2005 and related legislation, are requested to reserve time on the agenda by contacting Sandy Lonick by e-mail at Saundra.Lonick@usdoj.gov; or fax at (202) 307–3911. Requests must include the participant’s name, organization represented, if appropriate, and a brief VerDate Aug<31>2005 15:24 Mar 15, 2007 Jkt 211001 description of the issue. Each participant will be permitted approximately 3 to 5 minutes to present comments, depending on the number of individuals reserving time on the agenda. Participants are also encouraged to submit two written copies of their comments at the meeting. Given the expected number of individuals interested in presenting comments at the meeting, reservations should be made as soon as possible. Persons unable to obtain reservations to speak during the meetings are encouraged to submit written comments, which will be accepted at the meeting site or may be mailed to the Committee at 800 K Street, NW., Ste. 920, Washington, DC 20530. Mary Beth Buchanan, Acting Director, Office on Violence Against Women. [FR Doc. E7–4820 Filed 3–15–07; 8:45 am] BILLING CODE 4410–FX–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated July 26, 2006, and published in the Federal Register on August 2, 2006, (71 FR 43814–43815), Siegfried (USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: Drug Fmt 4703 Dated: March 9, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–4825 Filed 3–15–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Foreign Claims Settlement Commission [F.C.S.C. Meeting Notice No. 3–07] Sunshine Act Meeting II II II II II II II II II II II II The Foreign Claims Settlement Commission, pursuant to its regulations (45 CFR Part 504) and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice in regard to the scheduling of meetings for the transaction of Commission business and other matters specified, as follows: DATE AND TIME: Thursday, March 29, 2007, at 1 p.m. SUBJECT MATTER: Issuance of Proposed Decisions, Amended Proposed Decisions, and Amended Final Decisions in claims against Albania. STATUS: Open. All meetings are held at the Foreign claims Settlement Commission, 600 E Street, NW., Washington, DC. Requests for information, or advance notices of intention to observe an open meeting, may be directed to: Administrative Officer, Foreign Claims Settlement II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Siegfried (USA) Inc.’s application for renewal requested that DEA add Hydromorphone (9150) to its registration. DEA is reviewing this request. DEA’s granting of Siegfried (USA) Inc.’s application for renewal Frm 00046 does not include the authority to handle Hydromorphone (9150). When DEA has completed its review of the firm’s request to add Hydromorphone (9150) to its registration, DEA will publish its decision in the Federal Register. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Siegfried (USA), Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Siegfried (USA), Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Schedule Amphetamine (1100) .................... Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Glutethimide (2550) ...................... Codeine (9050) ............................. Oxycodone (9143) ........................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Methadone intermediate (9254) ... Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... PO 00000 12635 Sfmt 4703 E:\FR\FM\16MRN1.SGM 16MRN1

Agencies

[Federal Register Volume 72, Number 51 (Friday, March 16, 2007)]
[Notices]
[Page 12635]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-4825]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated July 26, 2006, and published in the Federal 
Register on August 2, 2006, (71 FR 43814-43815), Siegfried (USA), Inc., 
Industrial Park Road, Pennsville, New Jersey 08070, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the basic classes of controlled substances 
listed in schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Glutethimide (2550)........................  II
Codeine (9050).............................  II
Oxycodone (9143)...........................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Methadone intermediate (9254)..............  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    Siegfried (USA) Inc.'s application for renewal requested that DEA 
add Hydromorphone (9150) to its registration. DEA is reviewing this 
request. DEA's granting of Siegfried (USA) Inc.'s application for 
renewal does not include the authority to handle Hydromorphone (9150). 
When DEA has completed its review of the firm's request to add 
Hydromorphone (9150) to its registration, DEA will publish its decision 
in the Federal Register.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Siegfried (USA), Inc. to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Siegfried (USA), Inc. to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic classes of controlled substances listed.

    Dated: March 9, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-4825 Filed 3-15-07; 8:45 am]
BILLING CODE 4410-09-P